Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tecadenoson: CVTX completed enrollment of 180 patients in a double-blind, placebo-controlled U.S. and U.K. Phase III trial of tecadenoson to treat paroxysmal su

CV Therapeutics Inc. (CVTX), Palo Alto, Calif.
Product:

Read the full 82 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE